Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):111–115. doi: 10.1097/QAI.0000000000001481

Figure 1. Primary End Points.

Figure 1

Shown are unadjusted Kaplan-Meier estimates of time to discontinuation of first antiretroviral therapy (Panel A), and time to virologic failure of initial antiretroviral therapy (Panel B), by antiretroviral therapy regimen type. Panels C and D show unadjusted Kaplan-Meier estimates of time to discontinuation and time to virologic failure, respectively, restricting to patients initiating INSTI and NNRTI regimens 2007 and later.